06 October 2026
06 October 2026
Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma explores the method’s vision-restoring potential.
The pair will work together to progress lixudebart across multiple rare kidney and liver diseases.
Lilly is continuing to bet on the molecular gate approach, which Gate says could create therapies targeting hard-to-drug proteins.
Combined with the AstraZeneca's genomic medicine facility, the site will accommodate around 2,000 researchers and scientists.
The companies expect the first commercial sale under the partnership to occur in 2027.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
